OBJECTIVE: To systematically evaluate the efficacy and safety of formula granules of Liangfu pill in the treatment of epigastric pain. METHODS: PubMed

Web of Science

Cochrane Central Register of Controlled Trials（CENTRAL）

MEDLINE

Embase

CNKI

VIP and CBM were retrieved to collect the randomized controlled trials（RCT） of formula granules of Liangfu pill in the treatment of epigastric pain till Feb. 10 th

2022. Stata 12.0 software was used to perform Meta-analysis on outcome indicators such as the total effective rate and recovery rate

the pain degree

duration and number of episodes of epigastric pain

and the safety was evaluated. RESULTS: Totally 11 RCT were enrolled

including 1 056 patients. Meta-analysis showed that compared with Liangfu pill decoction

formula granules of Liangfu pill could significantly improve the cure rate and overall effective rate of patients with epigastric pain（cure rate: RR=0.74

95%CI=0.65-0.84; total effective rate: RR=0.87

95%CI=0.83-0.91）

the differences were statistically significant（P<0.05）. Compared with decoction

formula granules of Liangfu pill was more effective in improving the pain degree

duration and frequency of epigastric pain（pain degree: RR=0.86

95%CI=0.71-1.02; duration of pain: RR=0.89

95%CI=0.74-1.04; frequency of pain: RR=0.69

95%CI=0.54-0.84）

the differences were statistically significant（P<0.05）. Meanwhile

compared with Liangfu pill decoction

formula granules of Liangfu pill could significantly reduce the overall incidence of adverse drug reactions in patients

the difference was statistically significant（RR=0.41

95%CI=0.19-0.88

P<0.05）. CONCLUSIONS: Compared with Liangfu pill decoction

formula granules of Liangfu pill in the treatment of patients with epigastric pain can further improve the overall efficacy and relieve pain. Limited by the quality of the included literature and the number of samples

the above conclusions still need to be verified by more high-quality

multicenter and large-sample RCT.